Neurology
🇺🇸 FDA Page 3FDA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Gain critical insights into global neurology drug development, clinical trials, regulatory approvals, and market trends. Inform your pharma strategy.
Showing 25–36 of 63 articles
Teva Reports Strong Q1 2026 Results as PONLIMSI Biosimilar Receives FDA Approval and Olanzapine LAI Advances
Teva Acquires Emalex Biosciences for First-in-Class Tourette Syndrome Drug Ecopipam
Bayer Presents 13 Stroke Research Abstracts at ESOC 2026, Including Asundexian Phase III Trial Data
Alzheimer's Clinical Trial Failures: Novo Nordisk's Semaglutide Phase 3 Outcome & Market Impact
Alzheimer's Clinical Trial Failures: Impact of Posdinemab Phase 2 Failure on Drug Development
Alzheimer's Clinical Trial Failures: Impact on US Market & Investment
BRC Therapeutics Receives FDA Clearance for BRC-002 Phase I Trial in Complex Regional Pain Syndrome
DMX-200 ACTION3 Trial Maintains Statistical Power Above 90% Following Blinded Data Review
FDA Breakthrough Therapy Designations: Impact on Neurological Disorder Investments 2026
FDA Approves Otarmeni: First Gene Therapy for Genetic Hearing Loss Under Priority Voucher Program
FDA Accelerates Mental Health Treatment Access Following Presidential Executive Order on Serious Mental Illness
Miracell's SMART M-CELL Stem Cell Therapy Shows Cognitive Improvement in Severe Alzheimer's Patients